Peripheral embolization to the lower extremity arteries arising from a mechanical (prosthetic) heart valve defines a distinct clinical scenario. Anticoagulation strategy in this population follows specific evidence-based recommendations, because not all agents perform equally when the embolic source is a mechanical valve.
Peripheral embolization to the lower extremity arteries where the source of embolism is a mechanical (prosthetic) heart valve or another cardiac origin. This setting demands careful selection of anticoagulation, as certain agents are preferred over others in this specific context.
Management centres on full-dose anticoagulation using a vitamin K antagonist, adjusted to reach a defined therapeutic range. The complete protocol — including monitoring requirements, management of out-of-range values, and considerations for this specific valve population — is available in the structured regimen.
DOI: 10.3389/fcvm.2021.773214
This recommendation also applies to patients with peripheral embolization caused by prosthethic heart valves or other cardiac sources of embolism.
Warfarin can of course still be used as an alternative for prevention of systemic thromboembolic events in patients with AF or other sources of embolism to peripheral arteries, however, and is superior to dabigatran in patients with mechanical heart valves and to rivaroxaban in those with antiphospholipid syndrome.
The therapeutic target is an international normalized ratio (INR) of 2.0-3.0.
View source ↗